LLY

724.66

-1.16%↓

JNJ

153.29

-0.44%↓

UNH

382.24

+0.49%↑

ABBV

188.31

+2.2%↑

ABT

132.44

-0.62%↓

LLY

724.66

-1.16%↓

JNJ

153.29

-0.44%↓

UNH

382.24

+0.49%↑

ABBV

188.31

+2.2%↑

ABT

132.44

-0.62%↓

LLY

724.66

-1.16%↓

JNJ

153.29

-0.44%↓

UNH

382.24

+0.49%↑

ABBV

188.31

+2.2%↑

ABT

132.44

-0.62%↓

LLY

724.66

-1.16%↓

JNJ

153.29

-0.44%↓

UNH

382.24

+0.49%↑

ABBV

188.31

+2.2%↑

ABT

132.44

-0.62%↓

LLY

724.66

-1.16%↓

JNJ

153.29

-0.44%↓

UNH

382.24

+0.49%↑

ABBV

188.31

+2.2%↑

ABT

132.44

-0.62%↓

Search

Recursion Pharmaceuticals Inc

Closed

SectorHealthcare

4.32 -2.04

Overview

Share price change

24h

Current

Min

4.32

Max

4.41

Key metrics

By Trading Economics

Income

-24M

-202M

Sales

10M

15M

EPS

-0.5

Profit margin

-1,373.259

Employees

800

EBITDA

-26M

-191M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+55.89% upside

Dividends

By Dow Jones

Next Earnings

7 sie 2025

Market Stats

By TradingEconomics

Market Cap

-1.2B

2.3B

Previous open

6.36

Previous close

4.32

News Sentiment

By Acuity

100%

0%

373 / 382 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 maj 2025, 23:48 UTC

Earnings
Acquisitions, Mergers, Takeovers

Dyno Nobel Returns to 1st Half Profit; Strikes Fertilizers Deals -- Update

11 maj 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-China Trade Talks -- Market Talk

11 maj 2025, 23:45 UTC

Market Talk

Oil Rises Amid Improved Market Mood -- Market Talk

11 maj 2025, 23:38 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Aristocrat Has Significant Firepower for M&A -- Market Talk

11 maj 2025, 23:36 UTC

Market Talk

Global Markets Uncertain About US-China Trade News -- Market Talk

11 maj 2025, 23:35 UTC

Market Talk

Gold Falls, Dragged by Weakening Safe-Haven Demand, Possible Profit-Taking -- Market Talk

11 maj 2025, 23:33 UTC

Earnings
Acquisitions, Mergers, Takeovers

Dyno Nobel Returns to 1H Profit; Strikes Fertilizers Deals -- Update

11 maj 2025, 23:32 UTC

Top News

Proposal Cutting Medicaid Aims for GOP Middle Ground -- WSJ

11 maj 2025, 22:44 UTC

Market Talk

Centaurus Metals's Jaguar Project Faces Funding Hurdles -- Market Talk

11 maj 2025, 22:33 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Domain Takeover Could Create Near-Term Overhang on REA Stock -- Market Talk

11 maj 2025, 20:19 UTC

Top News

Bessent Says U.S.-China Trade Talks Were 'Productive,' Without Offering Specifics -- WSJ

11 maj 2025, 16:00 UTC

Top News

Trump's Budget Hawk Takes Over the DOGE Agenda. First Up: the Military -- WSJ

11 maj 2025, 11:00 UTC

Top News

This Obscure New York Court Is Set to Decide Fate of Trump's Tariffs -- WSJ

11 maj 2025, 08:00 UTC

Top News

China's Property Market Is a Tale of Big Cities. Everywhere Else Is Struggling. -- Barrons.com

11 maj 2025, 01:00 UTC

Top News

The Spring Home Sales Season Is Shaping Up to Be a Dud -- WSJ

11 maj 2025, 01:00 UTC

Top News

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia on Cease-Fire -- WSJ

10 maj 2025, 21:54 UTC

Top News

GOP Tax Bill Seeks to Put Cash in Taxpayers' Pockets in Early 2026 -- Update

10 maj 2025, 17:12 UTC

Top News

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia to Cease Fire -- WSJ

10 maj 2025, 15:41 UTC

Top News

Fed Officials Signal Pause on Adjusting Interest Rates as Trade Risks Mount -- Barrons.com

10 maj 2025, 12:00 UTC

Top News

Why a Sorority Is Taking on Trump's Budget Cuts -- WSJ

10 maj 2025, 09:30 UTC

Top News

The Giants of Silicon Valley Are Having a Midlife Crisis Over AI -- WSJ

10 maj 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

10 maj 2025, 03:52 UTC

Top News

China Struggles With Persistent Disinflationary Pressures as Tariffs Bite -- WSJ

9 maj 2025, 23:51 UTC

Acquisitions, Mergers, Takeovers

Oil at $50? The High Cost of Cheap Crude. -- Barrons.com

9 maj 2025, 22:06 UTC

Market Talk

Arm Holdings Remains a Strong Growth Story -- Market Talk

9 maj 2025, 21:37 UTC

Top News

U.S. Sets August Deadline for Debt Ceiling -- WSJ

9 maj 2025, 21:10 UTC

Top News

The Score: Disney, Berkshire Hathaway, Ford and More Stocks That Defined the Week -- WSJ

9 maj 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9 maj 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

9 maj 2025, 20:42 UTC

Top News

Stocks Get a Break From Trade Chaos -- WSJ

Peer Comparison

Price change

Recursion Pharmaceuticals Inc Forecast

Price Target

By TipRanks

55.89% upside

12 Months Forecast

Average 6.75 USD  55.89%

High 8 USD

Low 3 USD

Based on 5 Wall Street analysts offering 12 month price targets forRecursion Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

1

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

4.15 / 4.75Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

373 / 382 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.